Current patent status of histone deacetylase inhibitors
- 1 September 2002
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 12 (9), 1375-1384
- https://doi.org/10.1517/13543776.12.9.1375
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Structure and Chemistry of Apicidins, a Class of Novel Cyclic Tetrapeptides without a Terminal α-Keto Epoxide as Inhibitors of Histone Deacetylase with Potent Antiprotozoal ActivitiesThe Journal of Organic Chemistry, 2002
- Histone deacetylase inhibitors in cancer treatmentAnti-Cancer Drugs, 2002
- Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and TrapoxinOrganic Letters, 2001
- Chronic Oral Administration of CI-994: A Phase I StudyInvestigational New Drugs, 2001
- The Human Histone Deacetylase FamilyExperimental Cell Research, 2001
- Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxinProceedings of the National Academy of Sciences, 2000
- Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide DerivativesJournal of Medicinal Chemistry, 1999
- Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylaseOncogene, 1999
- FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase InhibitorExperimental Cell Research, 1998
- Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitroEuropean Journal Of Cancer, 1996